Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe.

dianagosalvez Diana Gosalvez Prados última modificación 6/10/2014 10:25

Combined oral anticoagulant (OAC) and antiplatelet (AP) therapy is generally discouraged in atrial fibrillation (AF) outside of acute coronary syndromes or stenting because of increased bleeding. We evaluated its frequency and possible reasons in a contemporary European AF population.

De Caterina R et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014 Oct 15;100(20):1625-35. Available at: http://heart.bmj.com/content/100/20/1625.long


Artículo

6/10/2014
None

De Caterina R et al.

Resto de la Unión Europea